Gain Therapeutics, Inc.
GANX Nasdaq
SEC CIK 1819411
Follow Gain Therapeutics
Weekly email: filings, results
Net income
−$3.2M
+40.2% vs same quarter last year
EPS, diluted
−$0.07
+53.3% vs same quarter last year
Operating cash flow
−$3M
+38.1% vs same quarter last year
Operating income
−$3.2M
+33.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$20.2M |
| FY24 | - | −$20.4M |
| FY23 | $55.2K | −$22.3M |
| FY22 | $132.6K | −$17.6M |
| FY21 | $133.9K | −$13.9M |
| FY20 | $28.9K | −$3.6M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | −40328.3% | −40354.3% |
| FY22 | −13402.5% | −13262% |
| FY21 | −10323.6% | −10371.7% |
| FY20 | −12047.5% | −12387.7% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$18.9M |
| FY23 | −$18.9M |
| FY22 | −$14.8M |
| FY21 | −$12.5M |
| FY20 | −$3.3M |
| FY19 | - |
- Gain Therapeutics
- Healthcare median
Show the numbers
| Year | Gain Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | −40354.3% | −58% |
| FY22 | −13262% | −80.4% |
| FY21 | −10371.7% | −71.8% |
| FY20 | −12387.7% | −62.2% |
| FY19 | - | −46.2% |